Q3 2025 Beta Bionics Inc Earnings Call Transcript
Key Points
- Beta Bionics Inc (BBNX) reported a 63% year-over-year increase in net sales, reaching $27.3 million for Q3 2025.
- The company experienced a 68% year-over-year growth in new patient starts, with 5,334 new patients in the quarter.
- Gross margin improved to 55.5%, up from 53.4% in Q3 2024, driven by increased scale and manufacturing volume leverage.
- Over 80% of insured lives in the US are covered under formulary agreements with pharmacy benefit managers, enhancing market access.
- The iLet device continues to set a new standard in diabetes management, with its automation and adaptation simplifying the process for users and healthcare providers.
- Operating expenses increased by 62% year-over-year, reaching $32.2 million, driven by sales and marketing expansion and R&D costs.
- The company received an FDA Form 483 related to its customer complaint handling system, requiring remediation efforts.
- Only 30% of new patient starts were reimbursed through the pharmacy channel, indicating a gap between covered lives and actual pharmacy benefit adoption.
- The company faces challenges in predicting the future percentage of new patient starts through the pharmacy channel.
- There is uncertainty regarding the timeline for the commercialization of the Mint patch pump and the bihormonal system, with potential delays due to regulatory processes.
Good afternoon and welcome to the Beta Bionics third-quarter 2025 earnings conference call. (Operator Instructions) As a reminder, please be advised that today's conference is being recorded.
I would like to hand the conference over to Blake Beber, Head of Investor Relations. Please go ahead.
Good afternoon and thank you for tuning in to Beta Bionics' third-quarter 2025 earnings call. Joining me for today's call are Chief Executive Officer, Sean Saint; and Chief Financial Officer, Stephen Feider.
Both the replay of this call and the press release discussing our third-quarter 2025 results will be available on the Investor Relations section of our website. The replay will be available for approximately one year following the conclusion of this call.
Information recorded on this call speaks only as of today, October 28, 2025. Therefore, if you are listening to any replay, any time sensitive information may no longer be accurate. Also on our website is our supplemental third
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
